首頁(yè)
瀏覽量: 302
- 產(chǎn)品名稱： Research Grade Daclizumab ( 達(dá)克珠單抗 )
- 產(chǎn)品貨號(hào)： CSD00005
- 貨期： 現(xiàn)貨
- 價(jià)格與訂購(gòu)： 2480
- 數(shù)量：
庫(kù)存： 100
- 規(guī)格： 100μg
- 產(chǎn)品信息
- 如何訂購(gòu)
貨號(hào)（Catalog No.）
CSD00005
通用名INN
Daclizumab
純度(Purity
>95%
濃度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
內(nèi)毒素(Endotoxin level)
Please contact with the lab for this information.
產(chǎn)品描述(Description)
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences.The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.On 22 April 2008,Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized,for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2.Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab),as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis,was approved for use by the FDA in 2016.
別名(Alternative names)
BIIB019,DAC HYP
靶點(diǎn);物種(Specificity target name;species)
IL2RA[Homo sapiens]
種類(Species)
Humanized
受體鑒定(Receptor identification)
IgG1-kappa
分子量(MV)
142612.1 Da
CAS
152923-56-3
存儲(chǔ)條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .
地 址：
產(chǎn)品銷售：
E - mail ：
郵 編：
Amily
